Servier Pharmaceuticals/LinkedIn
Jul 27, 2025, 15:13
Potential Breakthrough for Glioma: Servier’s Therapy Nears EMA Approval – Servier Pharmaceuticals
Servier Pharmaceuticals shared a post on LinkedIn:
“Today, we received a positive CHMP opinion from the European Medicines Agency for our targeted therapy for Grade 2 IDH-mutant glioma.
If approved, this would mark the first significant treatment breakthrough for glioma in over two decades in the EU.
This milestone underscores our commitment to providing options for patients and their families and drive progress for all affected by glioma. Learn more about this news.”
More posts featuring Servier Pharmaceuticals.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 17, 2025, 01:33
Aug 16, 2025, 21:51
Aug 16, 2025, 21:38
Aug 16, 2025, 21:05
Aug 16, 2025, 20:40
Aug 16, 2025, 20:29